Literature DB >> 11592097

mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients.

A Marchetti1, F Buttitta, G Bertacca, K Zavaglia, G Bevilacqua, D Angelucci, P Viacava, A Naccarato, A Bonadio, F Barassi, L Felicioni, S Salvatore, F Mucilli.   

Abstract

Histological detection of axillary lymph node metastases is still the most valuable prognostic parameter for breast cancer, but about 30% of node-negative patients relapse within five years, suggesting that current methods are inadequate for identifying metastatic disease. More sensitive, PCR-based methods for the detection of metastatic cells are now available, enabling the amplification of cancer cell-specific mRNA messages by the RT-PCR assay. An ideal tumour marker, consistently expressed in tumour samples and not at all in normal lymph nodes, remains to be identified. The present study first investigated the expression of seven mRNA markers, CEA, CK19, c-Met, mammaglobin, MUC-1, beta1-->GalNAc-T and p97, selected on the basis of their previously reported specificity for breast cancer cells. Eighteen lymph nodes were examined from patients without tumours. Only mammaglobin mRNA and CEA mRNA were not expressed in normal nodes. All of the other markers showed a band of expression in 17%-55% of cases, indicating that they are not breast cancer-specific. CEA mRNA and mammaglobin mRNA expression could be detected in 15/20 (75%) and 19/20 (95%) primary breast carcinomas, respectively. The expression of mammaglobin mRNA and CEA mRNA was then compared in axillary lymph nodes from 248 consecutive breast cancer patients, 89 with histologically documented lymph node metastasis and 159 without histological evidence of metastatic disease. Ninety-seven per cent of the patients with histologically involved nodes showed expression of mammaglobin mRNA, whereas CEA mRNA was expressed in 79% of these cases. In the group of patients with histologically negative lymph nodes, 46 (29%) and 32 (20%) were found to be positive for mammaglobin and CEA expression, respectively, indicating the presence of metastases not detected by routine histological examination of one lymph node section. These results show that both mammaglobin RT-PCR and CEA RT-PCR are useful tools for the detection of breast cancer metastases in axillary lymph nodes. The detection sensitivity of the mammaglobin RT-PCR is far superior to that of the CEA RT-PCR, allowing the diagnosis of occult metastases in nearly one-third of cases. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592097     DOI: 10.1002/path.943

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

1.  Mammaglobin-A immunohistochemistry in primary central nervous system neoplasms and intracranial metastatic breast carcinoma.

Authors:  Patrick J Cimino; Richard J Perrin
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-07

2.  Relationship between mammaglobin expression and estrogen receptor status in breast tumors.

Authors:  Xiao-feng Guan; Mohammad K Hamedani; Adewale Adeyinka; Christina Walker; Angela Kemp; Leigh C Murphy; Peter H Watson; Etienne Leygue
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

3.  Expression of human mammaglobin as a marker of bone marrow micrometastasis in breast cancer.

Authors:  Yunjiang Liu; Li Ma; Xianyi Liu; Li Wang
Journal:  Exp Ther Med       Date:  2011-12-22       Impact factor: 2.447

4.  Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study.

Authors:  William E Gillanders; Kaidi Mikhitarian; Renee Hebert; Patrick D Mauldin; Yuko Palesch; Christian Walters; Marshall M Urist; G Bruce Mann; Gerard Doherty; Virginia M Herrmann; Arnold D Hill; Oleg Eremin; Mohamed El-Sheemy; Richard K Orr; Alvaro A Valle; Michael A Henderson; Robert L Dewitty; Sonia L Sugg; Eric Frykberg; Karen Yeh; Richard M Bell; John S Metcalf; Bruce M Elliott; Thomas Brothers; Jay Robison; Michael Mitas; David J Cole
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

5.  Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells.

Authors:  Michael Raynor; Sally-Anne Stephenson; David C A Walsh; Kenneth B Pittman; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2002-05-24       Impact factor: 4.430

6.  Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase-polymerase chain reaction.

Authors:  Ron Greenberg; Ignat Schwartz; Yehuda Skornick; Ofer Kaplan
Journal:  Breast Cancer Res       Date:  2003-03-06       Impact factor: 6.466

7.  Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph node metastasis.

Authors:  Wei Wei; Hui Hu; Haosheng Tan; Louis W C Chow; Adrian Y S Yip; Wings T Y Loo
Journal:  J Transl Med       Date:  2012-09-19       Impact factor: 5.531

8.  Quantitative evaluation of metastases in axillary lymph nodes of breast cancer.

Authors:  M Inokuchi; I Ninomiya; K Tsugawa; I Terada; K Miwa
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

9.  Technical limits of comparison of step-sectioning,immunohistochemistry and RT-PCR on breast cancer sentinel nodes: a study on methacarn-fixed tissue.

Authors:  Lorenzo Daniele; Laura Annaratone; Elena Allia; Sara Mariani; Enrico Armando; Martino Bosco; Luigia Macrì; Paola Cassoni; Giuseppe D'Armento; Gianni Bussolati; Gabor Cserni; Anna Sapino
Journal:  J Cell Mol Med       Date:  2008-07-30       Impact factor: 5.310

10.  Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential.

Authors:  Aleksandra Markiewicz; Magdalena Książkiewicz; Marzena Wełnicka-Jaśkiewicz; Barbara Seroczyńska; Jarosław Skokowski; Jolanta Szade; Anna J Żaczek
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.